Tepezza Hearing Injury Could Have Been Avoided With Better Warnings, Lawsuit Claims
Plaintiff indicates the Tepezza hearing injury came after she received several infusions of the thyroid eye disease drug.
Plaintiff indicates the Tepezza hearing injury came after she received several infusions of the thyroid eye disease drug.
The updated Tepezza label could significantly expand use of the thyroid eye disease treatment, even as lawsuits are being pursued over failure to warn about the hearing damage risks
Lawsuit indicates that neither the plaintiff nor her doctors were warned that Tepezza infusions could cause hearing loss and tinnitus, which persists long after the thyroid eye disease treatments
Researchers indicate that a woman suffered both severe gastrointestinal problems and hearing loss from Tepezza, but the side effects resolved when the dosage was cut in half.
Lawsuits brought throughout the federal court system each involve similar allegations that Tepezza caused hearing problems, resulting in a request to centralize the cases in a Multidistrict Litigation (MDL)
Infusions of Tepezza caused hearing loss problems that were not disclosed by the drug maker, and could have been avoided if warnings about the importance of audiological monitoring had been provided, according to lawsuit.
Lawsuit alleges no warnings or information was provided about the risk of hearing damage from Tepezza, which could have been avoided with medical monitoring
Horizon Pharmaceuticals claims the Tepezza hearing loss lawsuit is preempted by federal law because the manufacturer would have been unlikely to change the label warnings without FDA permission.
Horizon has objected to the call to consolidate Tepezza hearing loss lawsuits, claiming the cases will be too different to benefit from pretrial coordination.
Plaintiffs say Horizon has failed to share key financial projections to shareholders of what will likely happen if Amgen buys Tepezza manufacturer Horizon Therapeutics